entinostat has been researched along with Cancer of Prostate in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " These results demonstrate that compound 2 and its combination with SAHA are potentially useful agents that warrant further preclinical development for treatment of prostate cancer." | 1.35 | Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. ( Belosay, A; Gediya, LK; Khandelwal, A; Njar, VC; Purushottamachar, P, 2008) |
| "Here, we exposed ERG-positive prostate cancer cell lines to HDAC inhibitors Trichostatin A (TSA), MS-275 and suberoylanilide hydroxamic acid (SAHA) with or without androgen deprivation." | 1.35 | Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. ( Björkman, M; Halonen, P; Iljin, K; Kaivanto, E; Kallioniemi, OP; Nees, M; Sara, H, 2008) |
| "We reasoned that pretreatment of tumors with HDIs could enhance the replication and spread of OVs within malignancies." | 1.35 | Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. ( Abdelbary, H; Arguello, M; Atkins, H; Bell, JC; Bismar, TA; Breitbach, C; Diallo, JS; Falls, T; Hiscott, J; Kirn, D; Leveille, S; Nguyên, TL; Snoulten, VE; Stojdl, DF; Vähä-Koskela, MJ; Vanderhyden, BC; Werier, J; Yasmeen, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gediya, LK | 1 |
| Belosay, A | 1 |
| Khandelwal, A | 2 |
| Purushottamachar, P | 1 |
| Njar, VC | 1 |
| Jadhavar, PS | 1 |
| Ramachandran, SA | 1 |
| Riquelme, E | 1 |
| Gupta, A | 1 |
| Quinn, KP | 1 |
| Shivakumar, D | 1 |
| Ray, S | 1 |
| Zende, D | 1 |
| Nayak, AK | 1 |
| Miglani, SK | 1 |
| Sathe, BD | 1 |
| Raja, M | 1 |
| Farias, O | 1 |
| Alfaro, I | 1 |
| Belmar, S | 1 |
| Guerrero, J | 1 |
| Bernales, S | 1 |
| Chakravarty, S | 1 |
| Hung, DT | 1 |
| Lindquist, JN | 1 |
| Rai, R | 1 |
| Mehndiratta, S | 1 |
| Wang, RS | 1 |
| Huang, HL | 1 |
| Su, CJ | 1 |
| Hsu, CM | 1 |
| Wu, YW | 1 |
| Pan, SL | 1 |
| Liou, JP | 1 |
| Bernardo, MM | 1 |
| Kaplun, A | 1 |
| Dzinic, SH | 1 |
| Li, X | 1 |
| Irish, J | 1 |
| Mujagic, A | 1 |
| Jakupovic, B | 1 |
| Back, JB | 1 |
| Van Buren, E | 1 |
| Han, X | 1 |
| Dean, I | 1 |
| Chen, YQ | 1 |
| Heath, E | 1 |
| Sakr, W | 1 |
| Sheng, S | 1 |
| Gameiro, SR | 1 |
| Malamas, AS | 1 |
| Tsang, KY | 1 |
| Ferrone, S | 1 |
| Hodge, JW | 1 |
| Björkman, M | 1 |
| Iljin, K | 1 |
| Halonen, P | 1 |
| Sara, H | 1 |
| Kaivanto, E | 1 |
| Nees, M | 1 |
| Kallioniemi, OP | 1 |
| Nguyên, TL | 1 |
| Abdelbary, H | 1 |
| Arguello, M | 1 |
| Breitbach, C | 1 |
| Leveille, S | 1 |
| Diallo, JS | 1 |
| Yasmeen, A | 1 |
| Bismar, TA | 1 |
| Kirn, D | 1 |
| Falls, T | 1 |
| Snoulten, VE | 1 |
| Vanderhyden, BC | 1 |
| Werier, J | 1 |
| Atkins, H | 1 |
| Vähä-Koskela, MJ | 1 |
| Stojdl, DF | 1 |
| Bell, JC | 1 |
| Hiscott, J | 1 |
| Shen, L | 1 |
| Ciesielski, M | 1 |
| Ramakrishnan, S | 1 |
| Miles, KM | 1 |
| Ellis, L | 1 |
| Sotomayor, P | 1 |
| Shrikant, P | 1 |
| Fenstermaker, R | 1 |
| Pili, R | 3 |
| Camphausen, K | 2 |
| Burgan, W | 1 |
| Cerra, M | 1 |
| Oswald, KA | 1 |
| Trepel, JB | 1 |
| Lee, MJ | 2 |
| Tofilon, PJ | 2 |
| Scott, T | 1 |
| Sproull, M | 1 |
| Qian, DZ | 2 |
| Ren, M | 1 |
| Wei, Y | 1 |
| Wang, X | 2 |
| van de Geijn, F | 1 |
| Rasmussen, C | 1 |
| Nakanishi, O | 1 |
| Sacchi, N | 1 |
| Marcu, MG | 1 |
| Jung, YJ | 1 |
| Lee, S | 1 |
| Chung, EJ | 1 |
| Trepel, J | 1 |
| Neckers, L | 1 |
| Kasman, L | 1 |
| Lu, P | 1 |
| Voelkel-Johnson, C | 1 |
| Wei, YF | 1 |
| Kato, Y | 1 |
| Cheng, L | 1 |
| Gediya, L | 1 |
| Njar, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin[NCT00926640] | Phase 1 | 28 participants (Actual) | Interventional | 2009-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 other studies available for entinostat and Cancer of Prostate
| Article | Year |
|---|---|
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Cycle; Cell Differentiatio | 2008 |
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Topics: Androgen Antagonists; Animals; Cell Line, Tumor; Crystallography, X-Ray; Histone Deacetylase 6; Hist | 2016 |
4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetyla | 2017 |
Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Culture Techniques; | 2015 |
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Topics: Apoptosis; Benzamides; Blotting, Western; Breast Neoplasms; Cell Proliferation; Female; Flow Cytomet | 2016 |
Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2008 |
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Topics: Animals; Benzamides; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; Female; Histone De | 2008 |
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Topics: Acetylation; Animals; Benzamides; Carcinoma, Renal Cell; Castration; CD8-Positive T-Lymphocytes; Dis | 2012 |
Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
Topics: Acetylation; Benzamides; Brain Neoplasms; Cell Cycle; Cell Survival; Enzyme Inhibitors; Glioma; Hist | 2004 |
Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Topics: Acetylation; Animals; Benzamides; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Cell Proliferation; H | 2004 |
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
Topics: Animals; Benzamides; Cell Line, Tumor; Drug Therapy, Combination; Enzyme Inhibitors; Epigenesis, Gen | 2005 |
Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.
Topics: Antineoplastic Agents; Benzamides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; P | 2005 |
Curcumin is an inhibitor of p300 histone acetylatransferase.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Curcumin; | 2006 |
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Caspase | 2007 |
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Cycle; Cell Divi | 2007 |
MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cell Lin | 2008 |